AstraZeneca today announced that FDA has approved selumetinib for the treatment of pediatric patients, 2 years of age and older, with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). The FDA press release announcing the selumetinib approval is at

The SPRINT trial that was the basis for the selumetinib approval was an NCI/CTEP-sponsored clinical trial that led to selumetinib being available today for children with NF1-associated plexiform neurofibromas.

CTIS, Inc. is a contractor of NCI/CTEP that has developed and maintains CTEP-ESYS (CTEP Enterprise System), which was used to support the information and data needs during the conduct of this trial. CTEP-ESYS enables NCI/CTEP and the scientific community to focus on scientific opportunity, patient safety and finding better ways to treat, control and cure cancer.

CTIS is honored to support NCI/CTEP in their distinctive role to bring this new medicine to children and adults in need of more effective therapies.